Bioelectronic cell-based device provides a strategy for the treatment of the experimental model of multiple sclerosis

  • J Control Release. 2022 Nov 16;352:994-1008. doi: 10.1016/j.jconrel.2022.11.008.
Emilie Audouard  1 ,  Fanny Michel  2 ,  Vanessa Pierroz  2 ,  Taeuk Kim  2 ,  Lisa Rousselot  1 ,  Béatrix Gillet-Legrand  1 ,  Gaëlle Dufayet-Chauffaut  1 ,  Peter Buchmann  2 ,  Michael Florea  2 ,  Alexander Khel  3 ,  Kamilya Altynbekova  3 ,  Claudia Delgaldo  4 ,  Encarna Escudero  4 ,  Alejandra Ben Aissa Soler  4 ,  Nathalie Cartier  1 ,  Francoise Piguet  1 ,  Marc Folcher  5
Affiliations
  • 1. NeuroGenCell, Paris Brain Institute - ICM, INSERM, CNRS, AP-HP, Sorbonne Université; Hôpital de la Pitié Salpêtrière, Paris, France.
  • 2. Department of Biosystems Science and Engineering, D-BSSE, ETH Zürich, Basel, Switzerland.
  • 3. GeneXplain GmbH, Wolfenbuettel, Germany.
  • 4. Eurecat, Centre Tecnològic de Catalunya, Functional Printing and Embedded Devices Unit, Mataró, Spain.
  • 5. Department of Biosystems Science and Engineering, D-BSSE, ETH Zürich, Basel, Switzerland; Institute of Molecular and Clinical Ophthalmology, IOB, Basel, Switzerland. Electronic address: [email protected].
PMID: 36370877 DOI: 10.1016/j.jconrel.2022.11.008
Abstract

Wireless powered optogenetic cell-based implant provides a strategy to deliver subcutaneously therapeutic proteins. Immortalize Human Mesenchymal Stem Cells (hMSC-TERT) expressing the bacteriophytochrome diguanylate cyclase (DGCL) were validated for optogenetic controlled interferon-β delivery (Optoferon cells) in a bioelectronic cell-based implant. Optoferon cells transcriptomic profiling was used to elaborate an in-silico model of the recombinant interferon-β production. Wireless optoelectronic device integration was developed using additive manufacturing and injection molding. Implant cell-based optoelectronic interface manufacturing was established to integrate industrial flexible compact low-resistance screen-printed Near Field Communication (NFC) coil antenna. Optogenetic cell-based implant biocompatibility, and device performances were evaluated in the Experimental Autoimmune Encephalomyelitis (EAE) mouse model of multiple sclerosis.

Keywords
Bioelectronic; Cell-based device; Drug delivery; Interferon; Multiple sclerosis; Optogenetic.
Products